Reviewer’s report

Title: Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin Etabonate, a Novel SGLT2 Inhibitor, and Metformin when Co-administered in Subjects with Type 2 Diabetes Mellitus

Version: 4 Date: 11 February 2013

Reviewer: Mark S Fineman

Reviewer’s report:

The authors have satisfactorily addressed all of the points raised in the original manuscript review.

Major Compulsory Revisions: None

Minor Essential Revisions: None

Discretionary Revisions

1. Add information to the methods section on how metformin was measured

2. Discussion: Text says: “Mean lactate concentrations showed an increase or increasing trend during the three day MET BID treatment period. In contrast, the mean lactate concentrations decreased during RE BID and MET+RE BID periods”. Although it is clear that lactate increases in the met alone treatment, lactate does not decrease in the RE treatment arm. Would change to “In contrast, the mean lactate concentrations are unchanged or decreased slightly during RE BID and MET+RE BID periods.”

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.